Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Sockel

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Haematologica|August 31, 2019
The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup>FDG-PET/CT: final results from the prospective PETAML trialFriedrich Stölzel, Tors Lüer, Steffen Löck, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
Hemasphere|September 24, 2024
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDSPaolo Mazzeo, Christina Ganster, John Wiedenhöft, et al.
Nano Letters|August 14, 2020
Nanocytometer for smart analysis of peripheral blood and acute myeloid leukemia: a pilot studyJulian Schütt, Diana Isabel Sandoval Bojorquez, Elisabetta Avitabile, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
NPJ Digital Medicine|March 22, 2025
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification modelsJan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, et al.
Hemasphere|March 18, 2025
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistryHyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Leukemia|December 5, 2019
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agentsAnne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Haematologica|August 31, 2019
The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup>FDG-PET/CT: final results from the prospective PETAML trialFriedrich Stölzel, Tors Lüer, Steffen Löck, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
Hemasphere|September 24, 2024
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDSPaolo Mazzeo, Christina Ganster, John Wiedenhöft, et al.
Nano Letters|August 14, 2020
Nanocytometer for smart analysis of peripheral blood and acute myeloid leukemia: a pilot studyJulian Schütt, Diana Isabel Sandoval Bojorquez, Elisabetta Avitabile, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
NPJ Digital Medicine|March 22, 2025
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification modelsJan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, et al.
Hemasphere|March 18, 2025
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistryHyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Leukemia|December 5, 2019
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agentsAnne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Pageof 10